vs
Side-by-side financial comparison of FLEX LTD. (FLEX) and Johnson & Johnson (JNJ). Click either name above to swap in a different company.
FLEX LTD. is the larger business by last-quarter revenue ($27.9B vs $24.6B, roughly 1.1× Johnson & Johnson). Johnson & Johnson runs the higher net margin — 20.8% vs 0.9%, a 19.9% gap on every dollar of revenue. On growth, FLEX LTD. posted the faster year-over-year revenue change (16.9% vs 9.1%). Johnson & Johnson produced more free cash flow last quarter ($5.5B vs $212.0M). Over the past eight quarters, FLEX LTD.'s revenue compounded faster (110.3% CAGR vs 7.2%).
Flex Ltd. is a Singaporean–American multinational manufacturing company. It is the third largest global electronics manufacturing services (EMS), original design manufacturer (ODM) company by revenue, behind only Pegatron for what concerns original equipment manufacturers. Flex's U.S. corporate headquarters are located in Austin, Texas. The company has manufacturing operations in over 30 countries, totaling about 172,000 employees.
Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 48 on the 2025 Fortune 500 list of the largest United States corporations. In 2025, the company was ranked 42th in the Forbes Global 2000.
FLEX vs JNJ — Head-to-Head
Income Statement — Q4 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $27.9B | $24.6B |
| Net Profit | $250.0M | $5.1B |
| Gross Margin | 2.5% | 67.6% |
| Operating Margin | 1.3% | 20.2% |
| Net Margin | 0.9% | 20.8% |
| Revenue YoY | 16.9% | 9.1% |
| Net Profit YoY | 12.6% | 49.1% |
| EPS (diluted) | $0.67 | $2.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $27.9B | — | ||
| Q4 25 | $7.1B | $24.6B | ||
| Q3 25 | $6.8B | $24.0B | ||
| Q2 25 | $6.6B | $23.7B | ||
| Q1 25 | $6.4B | $21.9B | ||
| Q4 24 | $6.6B | $22.5B | ||
| Q3 24 | $6.5B | $22.5B | ||
| Q2 24 | $6.3B | $22.4B |
| Q1 26 | $250.0M | — | ||
| Q4 25 | $239.0M | $5.1B | ||
| Q3 25 | $199.0M | $5.2B | ||
| Q2 25 | $192.0M | $5.5B | ||
| Q1 25 | $222.0M | $11.0B | ||
| Q4 24 | $263.0M | $3.4B | ||
| Q3 24 | $214.0M | $2.7B | ||
| Q2 24 | $139.0M | $4.7B |
| Q1 26 | 2.5% | — | ||
| Q4 25 | 9.6% | 67.6% | ||
| Q3 25 | 9.0% | 69.6% | ||
| Q2 25 | 8.7% | 67.9% | ||
| Q1 25 | 8.8% | 66.4% | ||
| Q4 24 | 9.1% | 68.3% | ||
| Q3 24 | 8.1% | 69.0% | ||
| Q2 24 | 7.5% | 69.4% |
| Q1 26 | 1.3% | — | ||
| Q4 25 | 5.5% | 20.2% | ||
| Q3 25 | 4.4% | 31.2% | ||
| Q2 25 | 4.7% | 27.3% | ||
| Q1 25 | 4.8% | 62.3% | ||
| Q4 24 | 5.1% | 17.3% | ||
| Q3 24 | 4.5% | 14.9% | ||
| Q2 24 | 3.7% | 25.6% |
| Q1 26 | 0.9% | — | ||
| Q4 25 | 3.4% | 20.8% | ||
| Q3 25 | 2.9% | 21.5% | ||
| Q2 25 | 2.9% | 23.3% | ||
| Q1 25 | 3.5% | 50.2% | ||
| Q4 24 | 4.0% | 15.2% | ||
| Q3 24 | 3.3% | 12.0% | ||
| Q2 24 | 2.2% | 20.9% |
| Q1 26 | $0.67 | — | ||
| Q4 25 | $0.64 | $2.08 | ||
| Q3 25 | $0.52 | $2.12 | ||
| Q2 25 | $0.50 | $2.29 | ||
| Q1 25 | $0.56 | $4.54 | ||
| Q4 24 | $0.67 | $1.41 | ||
| Q3 24 | $0.54 | $1.11 | ||
| Q2 24 | $0.34 | $1.93 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $20.1B |
| Total DebtLower is stronger | $3.8B | $41.4B |
| Stockholders' EquityBook value | $5.1B | $81.5B |
| Total Assets | $22.1B | $199.2B |
| Debt / EquityLower = less leverage | 0.73× | 0.51× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $2.4B | — | ||
| Q4 25 | $3.1B | $20.1B | ||
| Q3 25 | $2.2B | $18.6B | ||
| Q2 25 | $2.2B | $18.9B | ||
| Q1 25 | $2.3B | $38.8B | ||
| Q4 24 | $2.3B | $24.5B | ||
| Q3 24 | $2.6B | $20.3B | ||
| Q2 24 | $2.2B | $25.5B |
| Q1 26 | $3.8B | — | ||
| Q4 25 | $4.4B | $41.4B | ||
| Q3 25 | $3.7B | — | ||
| Q2 25 | $3.7B | — | ||
| Q1 25 | $3.7B | — | ||
| Q4 24 | $3.7B | $32.4B | ||
| Q3 24 | $3.7B | — | ||
| Q2 24 | $3.2B | — |
| Q1 26 | $5.1B | — | ||
| Q4 25 | $5.1B | $81.5B | ||
| Q3 25 | $5.0B | $79.3B | ||
| Q2 25 | $5.1B | $78.5B | ||
| Q1 25 | $5.0B | $78.1B | ||
| Q4 24 | $5.0B | $71.5B | ||
| Q3 24 | $5.0B | $70.2B | ||
| Q2 24 | $5.0B | $71.5B |
| Q1 26 | $22.1B | — | ||
| Q4 25 | $20.8B | $199.2B | ||
| Q3 25 | $19.5B | $192.8B | ||
| Q2 25 | $19.1B | $193.4B | ||
| Q1 25 | $18.4B | $193.7B | ||
| Q4 24 | $18.3B | $180.1B | ||
| Q3 24 | $18.6B | $178.3B | ||
| Q2 24 | $17.7B | $181.1B |
| Q1 26 | 0.73× | — | ||
| Q4 25 | 0.87× | 0.51× | ||
| Q3 25 | 0.73× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.74× | — | ||
| Q4 24 | 0.74× | 0.45× | ||
| Q3 24 | 0.74× | — | ||
| Q2 24 | 0.64× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $413.0M | $7.3B |
| Free Cash FlowOCF − Capex | $212.0M | $5.5B |
| FCF MarginFCF / Revenue | 0.8% | 22.3% |
| Capex IntensityCapex / Revenue | — | 7.5% |
| Cash ConversionOCF / Net Profit | 1.65× | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $1.1B | $19.7B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $413.0M | — | ||
| Q4 25 | $420.0M | $7.3B | ||
| Q3 25 | $453.0M | $9.2B | ||
| Q2 25 | $399.0M | $3.9B | ||
| Q1 25 | $433.0M | $4.2B | ||
| Q4 24 | $413.0M | $7.0B | ||
| Q3 24 | $319.0M | $8.0B | ||
| Q2 24 | $340.0M | $5.6B |
| Q1 26 | $212.0M | — | ||
| Q4 25 | $272.0M | $5.5B | ||
| Q3 25 | $303.0M | $8.0B | ||
| Q2 25 | $266.0M | $2.8B | ||
| Q1 25 | $321.0M | $3.4B | ||
| Q4 24 | $301.0M | $5.4B | ||
| Q3 24 | $216.0M | $7.0B | ||
| Q2 24 | $229.0M | $4.7B |
| Q1 26 | 0.8% | — | ||
| Q4 25 | 3.9% | 22.3% | ||
| Q3 25 | 4.5% | 33.4% | ||
| Q2 25 | 4.0% | 11.9% | ||
| Q1 25 | 5.0% | 15.4% | ||
| Q4 24 | 4.6% | 23.8% | ||
| Q3 24 | 3.3% | 31.0% | ||
| Q2 24 | 3.6% | 20.7% |
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | 7.5% | ||
| Q3 25 | 2.2% | 4.8% | ||
| Q2 25 | 2.0% | 4.4% | ||
| Q1 25 | 1.8% | 3.6% | ||
| Q4 24 | 1.7% | 7.2% | ||
| Q3 24 | 1.6% | 4.6% | ||
| Q2 24 | 1.8% | 4.3% |
| Q1 26 | 1.65× | — | ||
| Q4 25 | 1.76× | 1.43× | ||
| Q3 25 | 2.28× | 1.78× | ||
| Q2 25 | 2.08× | 0.70× | ||
| Q1 25 | 1.95× | 0.38× | ||
| Q4 24 | 1.57× | 2.04× | ||
| Q3 24 | 1.49× | 2.97× | ||
| Q2 24 | 2.45× | 1.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FLEX
Segment breakdown not available.
JNJ
| Other | $14.2B | 58% |
| Immunology | $2.5B | 10% |
| Orthopaedics | $1.5B | 6% |
| Neuroscience | $1.4B | 6% |
| Cardiovascular | $1.4B | 6% |
| Surgery | $1.1B | 4% |
| Pulmonary Hypertension | $865.0M | 4% |
| Cardiovascular Metabolism Other | $794.0M | 3% |
| Vision | $531.0M | 2% |
| Infectious Diseases | $303.0M | 1% |
